Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

TAK1 polyclonal antibody

 
ADI-KAS-ST009-C 25 µg 110.00 USD
 
ADI-KAS-ST009-E 100 µg 248.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:TGF-β-activated kinase-1
 
Host:Rabbit
 
Immunogen:Synthetic peptide corresponding to a portion of mouse TAK1.
 
UniProt ID:Q62073
 
GenBank ID:D76466
 
Species reactivity:Human, Mouse, Rat
Bovine, Chicken, Dog, Guinea pig, Hamster, Monkey, Porcine, Rabbit, Sheep, Xenopus
 
Applications:IHC (PS), WB
 
Recommended Dilutions/Conditions:Western Blot (1µg/ml, colorimetric)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
 
Purity Detail:Protein A affinity purified.
 
Formulation:Liquid. In PBS, pH 7.2, containing 50% glycerol and 0.09% sodium azide.
 
Handling:Avoid freeze/thaw cycles.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Scientific Background:TAK1 (TGF-beta-activated kinase-1) is a 65 kDa serine/threonine kinase that is a member of the MAPKKK family. TAK1 is involved in the regulation of transcription by the TGF-beta super family, as its kinase activity is stimulated by TGF-beta and bone morphogenetic protein (BMP).
 
ADI-KAS-ST009 IHC1
IHC Analysis: Human placenta tissue stained with TAK1, pAb at 10µg/ml.
ADI-KAS-ST009 IHC2
IHC Analysis: Human prostate tissue stained with TAK1, pAb at 10µg/ml.
ADI-KAS-ST009 IHC3
IHC Analysis: Human tonsil tissue stained with TAK1, pAb at 10µg/ml.
Please mouse over
ADI-KAS-ST009 IHC1 ADI-KAS-ST009 IHC2 ADI-KAS-ST009 IHC3

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
MAP3K
By biological activity:
MAP3K Polyclonal antibody
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,